These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18340009)

  • 1. Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2.
    Parini P; Gustafsson U; Davis MA; Larsson L; Einarsson C; Wilson M; Rudling M; Tomoda H; Omura S; Sahlin S; Angelin B; Rudel LL; Eriksson M
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1200-6. PubMed ID: 18340009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
    Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
    Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K; Pineda G; Newton RS; Fernandez ML
    Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase.
    Maciejak A; Leszczynska A; Warchol I; Gora M; Kaminska J; Plochocka D; Wysocka-Kapcinska M; Tulacz D; Siedlecka J; Swiezewska E; Sojka M; Danikiewicz W; Odolczyk N; Szkopinska A; Sygitowicz G; Burzynska B
    BMC Biotechnol; 2013 Aug; 13():68. PubMed ID: 24128347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits.
    Kurokawa J; Hayashi K; Toyota Y; Shingu T; Shiomi M; Kajiyama G
    Biochim Biophys Acta; 1995 Oct; 1259(1):99-104. PubMed ID: 7492622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity.
    Ness GC; Chambers CM; Lopez D
    J Lipid Res; 1998 Jan; 39(1):75-84. PubMed ID: 9469588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
    Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
    de Haan W; van der Hoogt CC; Westerterp M; Hoekstra M; Dallinga-Thie GM; Princen HM; Romijn JA; Jukema JW; Havekes LM; Rensen PC
    Atherosclerosis; 2008 Mar; 197(1):57-63. PubMed ID: 17868678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux.
    Argmann CA; Edwards JY; Sawyez CG; O'Neil CH; Hegele RA; Pickering JG; Huff MW
    J Biol Chem; 2005 Jun; 280(23):22212-21. PubMed ID: 15817453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
    Wilcox LJ; Barrett PH; Huff MW
    J Lipid Res; 1999 Jun; 40(6):1078-89. PubMed ID: 10357840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells.
    Hayashi K; Kurokawa J; Nomura S; Kuga Y; Ohkura Y; Kajiyama G
    Biochim Biophys Acta; 1993 Apr; 1167(2):223-5. PubMed ID: 8466953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.
    Pocathikorn A; Taylor RR; Mamotte CD
    Clin Exp Pharmacol Physiol; 2010 Apr; 37(4):471-6. PubMed ID: 19930424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol-lowering effects and potential mechanisms of different polar extracts from Cyclocarya paliurus leave in hyperlipidemic mice.
    Jiang C; Wang Q; Wei Y; Yao N; Wu Z; Ma Y; Lin Z; Zhao M; Che C; Yao X; Zhang J; Yin Z
    J Ethnopharmacol; 2015 Dec; 176():17-26. PubMed ID: 26477373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB.
    Telford DE; Edwards JY; Lipson SM; Sutherland B; Barrett PH; Burnett JR; Krul ES; Keller BT; Huff MW
    J Lipid Res; 2003 May; 44(5):943-52. PubMed ID: 12562847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation.
    Chen Y; Ku H; Zhao L; Wheeler DC; Li LC; Li Q; Varghese Z; Moorhead JF; Powis SH; Huang A; Ruan XZ
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):365-76. PubMed ID: 24233489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.